НовостиBenzingaPiper Sandler Maintains Overweight on Crescent Biopharma, Lowers Price Target to $32 Piper Sandler Maintains Overweight on Crescent Biopharma, Lowers Price Target to $32 Benzinga 2026.11.13 15:55 (GMT+0) Открыть на Benzinga Другие новости